Advanced pharmaceutical testing equipment ensures medication safety.

Are Your Medications Authentic? A New Testing Method for Betamethasone and Dexamethasone

Samir D’Costa in Health & Wellness October 2026 • 4 min read.

"UPLC-MS/MS offers a faster, more reliable way to ensure the quality and correct dosage of critical anti-inflammatory drugs."

Glucocorticosteroids, vital in managing inflammation and regulating immune responses, include betamethasone (BTM) and dexamethasone (DXM). These synthetic hormones are administered in various forms—oral, injectable, and topical—making them essential components in treating diverse conditions. However, the availability of differing dosage forms necessitates precise quality control to guarantee accurate and safe medication.

Traditional methods for quantifying BTM and DXM often present limitations in speed and sensitivity. Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) emerges as a cutting-edge solution, offering rapid and precise analysis. This technique minimizes solvent consumption and enhances the speed of analysis, making it an attractive alternative to conventional High-Performance Liquid Chromatography (HPLC).

This article explores the development, optimization, and validation of a UPLC-MS/MS method for quantifying BTM and DXM in pharmaceutical preparations. By combining UPLC with triple quadrupole tandem mass spectrometry, this approach offers enhanced sensitivity and specificity, ensuring accurate determination of these corticosteroids in tablets, injectables, and eye/ear drops. This method sets a new standard for pharmaceutical analysis, promising improved quality control and patient safety.

The Science Behind UPLC-MS/MS: How It Ensures Accuracy

Advanced pharmaceutical testing equipment ensures medication safety.

The UPLC-MS/MS method developed by researchers offers a significant leap forward in pharmaceutical analysis. Using an Acquity BEH C18 column with a stepwise gradient mobile phase of acetonitrile and acetic acid in water, the method precisely elutes and quantifies dexamethasone and betamethasone. This technique monitors specific transitions (451>361 m/z) in MRM mode, allowing for highly accurate measurements.

The method's effectiveness lies in its ability to deliver linear results across a broad concentration range (10 to 1500 ng/mL) for both BTM and DXM. Crucially, the limits of detection are as low as 1 ng/mL, with minimal relative error and standard deviation, ensuring reliable quantification even at trace levels. Here’s a breakdown of what makes this method so robust:

High Sensitivity: Detects even trace amounts of BTM and DXM.
Broad Linearity: Accurate across a wide range of concentrations.
Minimal Error: Ensures reliable and consistent results.
Specificity: Precisely identifies BTM and DXM without interference.

AI Search Multiple angles on this topic

Latest Research

Methods for Measuring Betamethasone and Dexamethasone

A review of analytical methods for drugs used to treat COVID-19 reports LC-MS/MS methods for dexamethasone, as well as rapid, accurate, and cost-effective RP-HPLC and TLC methods for measuring dexamethasone alongside other compounds in surface water or pharmaceutical samples. For betamethasone disodium phosphate (BMSP), the cited study describes existing approaches including UPLC-MS/MS, voltammetry, modified silica compounds, and RP-HPLC. A separate study on 12 glucocorticoid residues in aquatic foods cautions that inadequate separation can cause erroneous quantification because mass spectrometry alone cannot distinguish the species.

Counterpoints

Analytical Methods Have Limitations

A 1978 analysis reported results for 13 pharmaceutical formulations and found that strong bases caused betamethasone and its organic esters to degrade through a pseudo-first-order reaction in methylene chloride. The same source describes potential problems with color-based methods: evaporative concentration, incomplete color development, and limited specificity of the oxidation-reduction reaction for the 2-17 α-keto function. Separately, a technical support document attributes HPLC peak tailing for betamethasone and its impurities to secondary silanol interactions between residual silica-support silanols and polar regions of the steroid.

These features contribute to the method's ability to accurately determine the content of BTM and DXM in various pharmaceutical products, ensuring that medications contain the correct dosage and are free from contaminants. The method's validation adheres to rigorous ICH guidelines, confirming its reliability and suitability for routine pharmaceutical analysis.

The Future of Medication Quality Control

This UPLC-MS/MS method represents a significant advancement in ensuring the quality and safety of pharmaceutical preparations containing betamethasone and dexamethasone. Its enhanced sensitivity, specificity, and efficiency make it an ideal tool for routine analysis, ensuring that patients receive medications with the correct dosage and free from contaminants.

AI Search Multiple angles on this topic

Future Outlook

Market Outlook and Industry Structure

A market report forecasts betamethasone market trends from 2026 to 2034, with segmentation, competitive assessment, and analysis of drivers, challenges, and opportunities. Another report describes betamethasone production as concentrated among a limited number of Tier-1 pharmaceutical manufacturers with integrated chemical synthesis and formulation capabilities. A separate market forecast projects the Betamethasone Acetate market at US$457 million in 2026, growing at a 4.4% CAGR to US$751 million by 2034. One market outlook also anticipates greater integration of digital health and personalized medicine over the next 3–5 years, though this is a forecast rather than an established development.

Broader Context

Systemic Effects and Exposure

A ScienceDirect overview reports that excessive use of topical betamethasone can lead to systemic toxicity, citing an infant case with elevated intraocular pressure and cushingoid features. A 2020 review reports that prenatal betamethasone affects immune-system cells and that these alterations may have long-term consequences; it also describes changes to β-cells and possible epigenetic modifications in immune cells and β-cell precursors. A 2026 study set out to assess plasma and urinary concentrations of betamethasone and triamcinolone acetonide after intra-articular and peri-articular administration, including the suitability of WADA minimum reporting levels and washout periods.

The adoption of UPLC-MS/MS in pharmaceutical analysis signifies a broader trend towards more sophisticated and reliable quality control measures. As regulatory standards become more stringent and the demand for accurate medication dosing increases, techniques like UPLC-MS/MS will play a crucial role in safeguarding public health.

For consumers, this means greater confidence in the medications they rely on. Accurate and reliable testing methods ensure that pharmaceutical products meet the highest standards of quality, providing peace of mind and better health outcomes. This innovation sets the stage for continuous improvement in pharmaceutical analysis, reinforcing the commitment to patient safety and effective treatment.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.2174/1573412912666161018145227, Alternate LINK

Title: Validated Ultra Performance Liquid Chromatography-Tandem Mass Spectrometric Method For Determination Of Betamethasone Or Dexamethasone In Pharmaceuticals

Subject: Pharmaceutical Science

Journal: Current Pharmaceutical Analysis

Publisher: Bentham Science Publishers Ltd.

Authors: Mohammad Jamal Amer Shammout, Nursabah Elif Basci

Published: 2017-12-11

Everything You Need To Know

Why is it important to accurately determine the levels of betamethasone and dexamethasone in medications?

Accurately determining the levels of betamethasone (BTM) and dexamethasone (DXM) is crucial because these glucocorticosteroids are vital for managing inflammation and regulating immune responses. They are administered in various forms, such as oral, injectable, and topical, to treat diverse conditions. Differing dosage forms necessitate precise quality control to guarantee accurate and safe medication, ensuring patients receive the correct dosage and avoid potential harm from under- or over-medication. Thus, ensuring that the levels of BTM and DXM are accurately measured is essential for patient safety and therapeutic effectiveness.

What are the limitations of traditional methods for quantifying betamethasone and dexamethasone, and how does UPLC-MS/MS overcome these?

Traditional methods for quantifying betamethasone (BTM) and dexamethasone (DXM) often present limitations in speed and sensitivity. Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) overcomes these limitations by offering rapid and precise analysis. This technique minimizes solvent consumption and enhances the speed of analysis, making it an attractive alternative to conventional High-Performance Liquid Chromatography (HPLC). UPLC-MS/MS combines UPLC with triple quadrupole tandem mass spectrometry, enhancing sensitivity and specificity, ensuring accurate determination of these corticosteroids in tablets, injectables, and eye/ear drops.

How does the UPLC-MS/MS method ensure accuracy in measuring betamethasone and dexamethasone levels?

The UPLC-MS/MS method ensures accuracy through several key features. It uses an Acquity BEH C18 column with a stepwise gradient mobile phase of acetonitrile and acetic acid in water to precisely elute and quantify dexamethasone (DXM) and betamethasone (BTM). The method monitors specific transitions (451>361 m/z) in MRM mode, allowing for highly accurate measurements. It delivers linear results across a broad concentration range (10 to 1500 ng/mL) for both BTM and DXM, with limits of detection as low as 1 ng/mL. Minimal relative error and standard deviation ensure reliable quantification even at trace levels. These features contribute to the method's ability to accurately determine the content of BTM and DXM in various pharmaceutical products.

What is the significance of the UPLC-MS/MS method adhering to ICH guidelines?

The UPLC-MS/MS method's adherence to the International Council for Harmonisation (ICH) guidelines is highly significant because it confirms the method's reliability and suitability for routine pharmaceutical analysis. ICH guidelines provide a standardized framework for validating analytical procedures, ensuring that they meet specific criteria for accuracy, precision, specificity, detection limit, quantitation limit, linearity, range, and robustness. By adhering to these guidelines, the UPLC-MS/MS method demonstrates that it is a scientifically sound and dependable tool for quantifying betamethasone (BTM) and dexamethasone (DXM) in pharmaceutical preparations, thereby enhancing confidence in the quality control process and patient safety.

What implications does the UPLC-MS/MS method have for the future of medication quality control containing betamethasone and dexamethasone?

The UPLC-MS/MS method represents a significant advancement in ensuring the quality and safety of pharmaceutical preparations containing betamethasone (BTM) and dexamethasone (DXM). Its enhanced sensitivity, specificity, and efficiency make it an ideal tool for routine analysis, ensuring that patients receive medications with the correct dosage and free from contaminants. The method's ability to accurately quantify even trace amounts of BTM and DXM means that manufacturers can more confidently ensure product consistency and regulatory compliance. This can lead to improved patient outcomes, reduced risk of adverse effects, and enhanced trust in pharmaceutical products. Widespread adoption of UPLC-MS/MS could set a new standard for pharmaceutical analysis, promoting better quality control practices globally.